Publications by authors named "Karim Abdelazim"
Article Synopsis
- Alzheimer's disease is a major cause of dementia, especially in people over 60, with cases expected to rise significantly by 2050, highlighting the urgent need for effective treatments.
- Lecanemab, a monoclonal antibody that targets amyloid-beta plaques, has shown promise in slowing Alzheimer's progression, supported by positive clinical trial results and ongoing research to enhance understanding of its effects.
- A systematic review and meta-analysis of lecanemab at a dosage of 10 mg/kg revealed significant cognitive improvements in Alzheimer's patients, while also noting potential safety concerns that necessitate careful monitoring in clinical settings.
Astaxanthin (AXT) is a red fat-soluble pigment found naturally in aquatic animals, plants, and various microorganisms and can be manufactured artificially using chemical catalysis. AXT is a xanthophyll carotenoid with a high potential for scavenging free radicals. Several studies have investigated AXT efficacy against diseases such as neurodegenerative, ocular, skin, and cardiovascular hypertension, diabetes, gastrointestinal and liver diseases, and immuno-protective functions.
View Article and Find Full Text PDF